fbpx
Nigerian Law Enforcement agencies open investigations on Hawilti and company executives for criminal breach of trust, cheating, defrauding investors schemeRead more Famine looms in Somalia, but many ‘hunger hotspots’ are in deep troubleRead more Launch of the 3rd Edition of the Choiseul Africa Business Forum, a Must-Attend Event for the Business Community in Africa October 19th & 20th, 2022 in Casablanca, MoroccoRead more World’s Biggest Afrobeats Music Festival Afro Nation Extends Partnership with APO Group until 2025Read more Master Trainer (MT) National Meeting on Sustainable Coffee Practices Organized by The International Islamic Trade Finance Corporation in Collaboration with The Sustainable Coffee Platform of Indonesia (SCOPI)Read more Thai Ambassador met the Thai Community in Dar es Salaam and Zanzibar and visited the Buddhist Temple in TanzaniaRead more Generation Africa awards US$100,000 to two young agripreneurs from Kenya and Uganda in the fourth annual GoGettaz Agripreneur Prize Competition at the African Green Revolution Forum Summit in Kigali, RwandaRead more Medicaid Cancer Foundation and AstraZeneca celebrate Prostate Cancer Awareness month with the launch of Project Icon NigeriaRead more Eight Tokyo International Conference on African Development (TICAD8): President Barrow Discusses Inclusive Development in The Gambia with United Nations Development Programme (UNDP) Assistant AdministratorRead more Canon Central and North Africa is Embarking on the Much-Awaited Canon R Tour in Nigeria to Launch our Flagship R System Models and Experiential Opportunities to Test Drive its Revolutionary Mirrorless Range of ProductsRead more

US to buy 1.7 million courses of Merck’s Covid pill

show caption
The $1.2 billion dollar deal is for a drug called molnupiravir, which is currently being tested in a Phase 3 clinical trial of 1,850 people, with results expected by fall./AFP
Print Friendly and PDF

Jun 10, 2021 - 07:58 AM

WASHINGTON — The United States on Wednesday announced an agreement with Merck to buy 1.7 million courses of an experimental antiviral pill against Covid-19.

The $1.2 billion dollar deal is for a drug called molnupiravir, which is currently being tested in a global Phase 3 clinical trial of 1,850 people, with results expected by fall.

“This agreement is part of the Biden Administration’s whole-of-government approach to develop new COVID-19 treatments and to respond to the health needs of the public,” the Department of Health and Human Services said.

The US will only complete the deal if molnupiravir receives an emergency use authorization or full approval by the Food and Drug Administration.

Rob Davis, president of Merck, added the company “is pleased to collaborate with the US government on this new agreement that will provide Americans with Covid-19 access to molnupiravir.”

The company hopes to have more than 10 million courses of the five-day-treatment available by the end of 2021.

Molnupiravir, which Merck is developing in partnership with Ridgeback Biotherapeutics, is one of several investigational oral antivirals that are being tested against Covid-19.

Experts say these are needed because not everyone responds well to Covid-19 vaccines, and vaccine access still remains a major issue for much of the world.

Molnupiravir belongs to a class of antiviral called polymerase inhibitors, which work by targeting an enzyme that viruses need to copy their genetic material, and introducing mutations that leave them unable to replicate.

It has also shown effectiveness in lab studies against other viruses such as influenza, Ebola, and Venezuelan Equine Encephalitis virus, but hasn’t been authorized or approved for any of these diseases.

Early results from a Phase 2 trial showed that, among dozens of volunteers who tested positive at the start, none of those who received molnupiravir had any detectable virus by day five, while a quarter of those who received a placebo did.

The numbers are promising but the sample is too small to draw firm conclusions, which is why it is being studied in a much larger group now.

If they are shown to be effective, antivirals against Covid-19 will be most effective in the narrow window after a person tests positive but before the disease becomes severe.

By this stage much of the harm to patients’ health comes from their own immune systems going into overdrive and damaging their organs, rather than viral replication.

Other notable efforts include antivirals being developed by Roche in collaboration with Atea, and another by Pfizer that was developed specifically against Covid-19.

MAORANDCITIES.COM uses both Facebook and Disqus comment systems to make it easier for you to contribute. We encourage all readers to share their views on our articles and blog posts. All comments should be relevant to the topic. By posting, you agree to our Privacy Policy. We are committed to maintaining a lively but civil forum for discussion, so we ask you to avoid personal attacks, name-calling, foul language or other inappropriate behavior. Please keep your comments relevant and respectful. By leaving the ‘Post to Facebook’ box selected – when using Facebook comment system – your comment will be published to your Facebook profile in addition to the space below. If you encounter a comment that is abusive, click the “X” in the upper right corner of the Facebook comment box to report spam or abuse. You can also email us.